Efficacy and safety of recombinant human Ad-p53 injection combined with cisplatin in treating malig-nant pleural effusion:a Meta-analysis
10.3760/cma.j.issn.1673-422X.2015.05.005
- VernacularTitle:重组人 p53腺病毒注射液联合顺铂治疗恶性胸腔积液疗效及安全性的 Meta 分析
- Author:
Yanzhe ZHU
;
Guoping SUN
- Publication Type:Journal Article
- Keywords:
Pleural effusion,malignant;
Cisplatin;
Meta-analysis;
Recombinant human Ad-p53
- From:
Journal of International Oncology
2015;(5):336-341
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of recombinant human Ad-p53( rAd-p53) injection combined with cisplatin in treating malignant pleural effusion by conducting a Meta-analysis. Methods A comprehensive collection of randomized controlled studies(RCTs)of rAd-p53 combined with cisplatin versus single cisplatin in the treatment of malignant pleural effusion was retrieved form Cochrane Library,Pubmed, EMBase,CBM,CNKI,Wanfang and VIP databases. Meta-analysis was conducted by RevMan 5. 2 software. Results Ten RCTs involving 538 patients were identified in the study. The Meta-analysis results showed that rAd-p53 combined with cisplatin group had a higher hydrothorax total remission rate than single cisplatin group (RR = 1. 67,95% CI:0. 90-2. 01;Z = 5. 51,P = 0. 000 01). The PS score in rAd-p53 combined with cisplatin group was better than that in single cisplatin group(RR = 1. 76,95% CI:1. 45-2. 14;Z = 5. 69,P <0. 000 01). The incidence rate of adverse reaction of heating in the former was higher than that in the latter (RR = 3. 10,95% CI:2. 25-4. 27;Z = 6. 94,P < 0. 000 01). There were no significant differences in adverse reactions of chest pain(RR = 0. 99,95% CI:0. 50-1. 96;Z = 0. 04,P = 0. 97),gastrointestinal reaction (RR = 1. 16,95% CI:0. 90-1. 50;Z = 1. 13,P = 0. 26)and marrow suppression(RR = 1. 09,95% CI:0. 81-1. 47;Z = 0. 59,P = 0. 55)between the two groups. Conclusion rAd-p53 combined with cisplatin therapy for the treatment of malignant pleural effusion is superior to single cisplatin therapy. Mean while,fever is self-limited,and the safety is identified. It is worthy for promotion of rAd-p53 injection combined with cisplatin inclinical treatment of advanced malignant pleural effusion.
